Shares of GW Pharmaceuticals plc (GWPH) soared $46.25 (or +120.25%) to $84.71 on Monday's trading session after the company reported positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex(R) (cannabidiol or CBD) for the treatment of Dravet syndrome, a rare and severe form of epilepsy in children with no FDA-approved treatments
According to the company, Epidiolex was - in this study - generally well tolerated and achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo (p=0.01)
Epidiolex, GW Pharma's lead cannabinoid product candidate, is a liquid formulation of pure plant-derived CBD, which is in development for the treatment of a number of rare childhood-onset epilepsy disorders.
GW Pharmaceuticalsis focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer